Skip to main content
. Author manuscript; available in PMC: 2016 Nov 9.
Published in final edited form as: Nat Chem Biol. 2016 May 9;12(7):497–503. doi: 10.1038/nchembio.2079

Figure 6. ACC inhibitor prevents GPX4 protein degradation.

Figure 6

a. Effects of the mevalonate pathway modulators and ACC inhibitor on GPX4 abundance with or without FIN56. The corresponding gel is shown in Supplementary Fig. 12. b. Lipid peroxide levels upon TOFA or αToc treatments. c. Effects of TOFA and αToc on FIN56 lethality. d. Model of FIN56’s mechanism of action. Dotted arrows indicate the mechanistic details are still elusive. Statistical significance (paired two-tailed t-test) – *: p < 0.05, ††: p < 0.001, n.s.: not significant. Supplementary Fig. 11d also supports that the mevalonate pathway modulators did not change GPX4 abundance. a–c were performed in biological triplicates. mean and s.e.m. are shown in a; single representative results were shown in b and c. error-bars are s.e.m. of technical triplicates in c.